Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma

scientific article

Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4081/HR.2011.S3.E1
P932PMC publication ID3269216
P698PubMed publication ID22586509
P5875ResearchGate publication ID224959131

P2093author name stringDino Amadori
P2860cites workDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyQ24240568
Cardioprotective interventions for cancer patients receiving anthracyclinesQ24243021
Different anthracycline derivates for reducing cardiotoxicity in cancer patientsQ24244087
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomaQ28297805
ICRF-187 permits longer treatment with doxorubicin in women with breast cancerQ28324350
Risk factors for doxorubicin-induced congestive heart failureQ28328220
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsQ34199968
Adriamycin (NSC-123,127): a new antibiotic with antitumor activityQ34239108
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupQ34566901
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).Q34742742
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaQ40318856
Anthracyclines in the treatment of cancer. An overviewQ41637134
Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimenQ42248014
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusionQ42263291
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trialQ43223088
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaQ43864036
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.Q44776010
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.Q44796944
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaQ46546765
Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphomaQ46645702
Clinical evaluation of adriamycin, a new antitumour antibioticQ49203313
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127)Q71579286
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclinesQ80678386
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue3s
P304page(s)e1
P577publication date2011-10-01
P1433published inHematology reportsQ26841985
P1476titleMoving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma
P478volume3

Reverse relations

Q30455450Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.cites workP2860

Search more.